Stockreport

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Foghorn Therapeutics Inc.  (FHTX) 
PDF Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral b [Read more]